ANVISA Approves Polylaminin: Brazil's Breakthrough Treatment for Spinal Cord Injury
On April 21, 2026, Brazil's National Health Surveillance Agency (ANVISA) announced the approval of polylaminin-based therapy for the treatment of spinal cord injuries — a decision that sent ripples through the global medical community and offered hope to the estimated 250,000 Brazilians living with spinal cord injury-related paralysis. The approval makes Brazil the first country in the world to authorize a regenerative treatment specifically designed to promote nerve regrowth in damaged spinal tissue.
The announcement came after more than a decade of research led by Dr. Alexandre Fogaça Cristante and his team at the Institute of Orthopedics and Traumatology at the University of São Paulo's Hospital das Clínicas (HC-FMUSP), one of Latin America's largest and most respected medical institutions. The journey from laboratory discovery to clinical approval represents one of the most significant achievements in Brazilian biomedical research history — and potentially a turning point in how the world approaches one of medicine's most devastating injuries.
What Is Polylaminin?
The Science Behind the Name
Polylaminin is a biopolymer derived from laminin-111, a naturally occurring protein found in the extracellular matrix (ECM) — the complex network of molecules that surrounds and supports cells throughout the body. In the nervous system, laminin plays a crucial role in guiding axonal growth during embryonic development and supporting nerve cell survival in adult tissue.
The key innovation of the Brazilian team was discovering how to polymerize laminin into a stable, injectable form that retains its biological activity. When injected into the site of a spinal cord injury, polylaminin self-assembles into a three-dimensional scaffold that mimics the body's natural nerve-supporting structures. This scaffold serves three critical functions:
- Physical bridging: It fills the cavity left by the injury, providing a structural pathway for regenerating nerve fibers (axons) to grow across the damage zone.
- Biochemical signaling: The polymerized laminin actively stimulates axonal growth by binding to integrin receptors on nerve cell surfaces, triggering intracellular signaling cascades that promote growth cone extension.
- Anti-inflammatory modulation: Polylaminin has been shown to reduce the chronic inflammatory response that typically forms a glial scar around spinal cord injuries — a scar that acts as a physical and chemical barrier to nerve regeneration.
Why Previous Approaches Failed
Spinal cord injury has been called the "holy grail" of regenerative medicine because of the central nervous system's notoriously poor capacity for self-repair. Unlike the peripheral nervous system (which can regenerate after injury, allowing a cut finger nerve to regrow), the spinal cord creates a hostile environment for regrowth after damage.
Previous treatment approaches have fallen into several categories, each with significant limitations:
| Approach | Example | Limitation |
|---|---|---|
| Stem cell therapy | Geron Corp trials (2010) | Poor cell survival and integration at injury site |
| Growth factor delivery | BDNF, NT-3 injections | Rapid degradation; difficulty sustaining therapeutic levels |
| Nerve grafts | Peripheral nerve autografts | Donor site morbidity; limited scalability |
| Electrical stimulation | Epidural stimulation | Requires permanent implanted hardware; doesn't regenerate tissue |
| Exoskeleton-assisted | ReWalk, Ekso | Assistive only; no biological recovery |
Polylaminin addresses the fundamental problem that these approaches couldn't solve: creating a permissive environment for nerve regeneration within the hostile post-injury spinal cord.
The Clinical Trial Journey
Phase I/II (2019–2022): Safety and Proof of Concept
The first human trials began in 2019 at HC-FMUSP with 28 patients who had chronic incomplete spinal cord injuries. The primary endpoint was safety — determining whether injecting polylaminin into the injured spinal cord caused adverse effects. Secondary endpoints included changes in sensory and motor function as measured by the American Spinal Injury Association Impairment Scale (ASIA).
Results were encouraging: no serious adverse events were reported, and 7 of 28 patients (25%) showed measurable improvement in sensory function below the level of injury — a result that exceeded researchers' expectations for a Phase I safety trial.
Phase III (2023–2025): The Pivotal Trial
The Phase III trial enrolled 180 patients across five Brazilian medical centers: HC-FMUSP (São Paulo), Hospital Sarah Kubitschek (Brasília), Hospital das Clínicas de Belo Horizonte, Hospital Miguel Couto (Rio de Janeiro), and Hospital de Clínicas de Porto Alegre.
Patients were randomized 2:1 to receive either polylaminin injection plus standard rehabilitation, or saline injection (placebo) plus standard rehabilitation. The trial was double-blinded — neither patients nor their treating physicians knew which treatment was administered.
The results, published in The Lancet Neurology in February 2026, were striking:
| Outcome | Polylaminin Group (n=120) | Placebo Group (n=60) | p-value |
|---|---|---|---|
| Any sensory improvement | 38% | 12% | p < 0.001 |
| Partial motor recovery | 22% | 5% | p < 0.001 |
| ASIA grade improvement (≥1 grade) | 18% | 3% | p < 0.001 |
| Serious adverse events | 4.2% | 3.3% | NS |
| Pain at injection site | 67% | 45% | p = 0.01 |
The most dramatic cases involved three patients who regained the ability to voluntarily move their toes and feet — movements that had been impossible for years prior to treatment. While this doesn't represent full recovery, for patients who have lived without any voluntary lower limb movement, the ability to wiggle a toe is emotionally and clinically transformative.
ANVISA's Decision and What It Means
The Regulatory Framework
ANVISA's approval was granted under its "Innovative Therapy" pathway, a regulatory framework created in 2023 specifically to accelerate the review of novel biological therapies that address unmet medical needs. The approval was conditional on continued post-marketing surveillance and the completion of a 5-year follow-up study on all Phase III participants.
The approved indication is specific: polylaminin therapy for patients with incomplete spinal cord injuries classified as ASIA B, C, or D, who are between 6 months and 5 years post-injury. Patients with complete spinal cord transection (ASIA A) are excluded from the current approval, as the Phase III trial did not include enough ASIA A patients to demonstrate efficacy in this population.
Access and Cost
The treatment will initially be available at five certified neurosurgical centers. Each treatment cycle involves a single image-guided injection of polylaminin directly into the injury site, performed under general anesthesia. The procedure takes approximately 90 minutes, with a 48-hour hospital observation period.
The estimated cost per treatment cycle is R$85,000 (approximately $15,000 USD). ANVISA has recommended that the Brazilian public health system (SUS) include polylaminin in its formulary, which would make it available at no cost to qualifying patients. The Ministry of Health is expected to make a coverage decision by September 2026.
Global Impact and International Interest
The International Response
The ANVISA approval immediately attracted international attention. The US Food and Drug Administration (FDA) reportedly reached out to the Brazilian research team within 48 hours of the announcement to discuss potential expedited review pathways. The European Medicines Agency (EMA) issued a statement noting that it was "following developments with great interest."
Japan's Pharmaceuticals and Medical Devices Agency (PMDA), which has historically been more receptive to regenerative therapies than Western regulators, announced plans to fast-track review of polylaminin under its conditional approval system for regenerative medicines.
Why Brazil First?
The fact that this breakthrough came from Brazil — rather than the US, Europe, or Japan — is significant. Brazilian neuroscience research has been consistently underfunded relative to the country's scientific talent pool, and the polylaminin program survived multiple funding crises over its 15-year development. Dr. Cristante has publicly credited FAPESP (the São Paulo Research Foundation) and persistent support from HC-FMUSP's institutional leadership for keeping the program alive during periods when federal research funding was cut.
The success also highlights a broader trend: countries outside the traditional biomedical research powerhouses are increasingly producing world-class innovations, often in areas that large pharmaceutical companies have deprioritized due to small market size or long development timelines.
What This Means for the 250,000 Brazilians with Spinal Cord Injuries
Brazil records approximately 11,000 new spinal cord injuries per year, primarily from traffic accidents (42%), falls (27%), and violence (including gunshot wounds, 24%). The majority of victims are young men aged 18–35, and the economic burden — including lost productivity, lifetime care costs, and disability payments — exceeds R$12 billion annually.
For these patients and their families, polylaminin represents something that has been absent from spinal cord injury medicine for decades: hope grounded in evidence. Not a miracle cure, not an experimental procedure requiring travel to an overseas clinic, but a rigorously tested, domestically developed treatment approved by their own regulatory authority.
The road ahead remains long. Polylaminin doesn't restore full function, and many patients who receive it won't experience dramatic improvement. But in a field where the standard of care has been essentially unchanged since the 1970s — stabilize the spine, manage complications, and rehabilitate whatever function remains — any treatment that demonstrably improves neurological outcomes represents a genuine revolution.
Sources and References
- The Lancet Neurology — Polylaminin Phase III Results, February 2026
- ANVISA — Innovative Therapy Approval Notice, April 2026
- FAPESP — Research Grant History for Polylaminin Program
- American Spinal Injury Association — ASIA Impairment Scale
- HC-FMUSP — Institute of Orthopedics and Traumatology
